- The European Commission has granted marketing authorisation across the EU to Pebrilzo, Biocon's biosimilar of the breast cancer medicine pertuzumab.
- It is the first biosimilar approved under the European Medicines Agency's new tailored clinical approach, and it follows a recent US FDA approval for the same product.
- Biocon says pertuzumab is now its fifth cancer biosimilar approved in both Europe and the United States.
What it means for Biocon's business
A new cancer medicine to sell in Europe
- Biocon can now sell its pertuzumab biosimilar across the EU, widening its range of cancer medicines there.
- Sales start only when it launches country by country, and will depend on price and on how many rival versions launch.
Pairs with a medicine Biocon already has
- Pertuzumab is given together with trastuzumab, and Biocon already has an approved trastuzumab biosimilar. It can now offer hospitals both medicines used in the same treatment.
Two big markets for one product
- With approvals in both the US and the EU, one development effort can earn revenue in two of the largest markets for biologic medicines.
- If more of its biosimilars qualify for the EMA's tailored approach, Biocon could spend less time and money on large patient trials.
What the filing says
The approval
- It covers HER2-positive breast cancer at several stages: early, locally advanced, inflammatory and metastatic disease.
- The medicine is given by infusion as a 420 mg concentrate, together with trastuzumab and chemotherapy.
- The EMA's scientific committee (CHMP) gave a positive opinion on 17 September 2026; the European Commission's decision completes the approval.
How it was approved
- Biocon says detailed lab tests of the molecule's structure and function, plus comparative pharmacokinetic data in people, showed it is highly similar to the original medicine.
- It reports no clinically meaningful differences in quality, safety or efficacy.
Why it matters
What a biosimilar is
- A biosimilar is a close copy of a biologic medicine, sold once the original's protection ends, usually at a lower price.
- The original pertuzumab medicine is sold by Roche as Perjeta.
Why the approval route matters
- Under the EMA's tailored approach, a biosimilar can rely mainly on lab comparisons and pharmacokinetic data rather than a large efficacy trial in patients.
- Biocon says its pertuzumab is the first biosimilar approved this way.
What the filing does not say
- It gives no launch date, prices or partners for European countries.
- It does not say how much revenue Biocon expects from the product.
What to watch next
- Launch timing in EU countries, and any update on the product in Biocon's next quarterly results and earnings call.
Source: Exchange filings
Biocon: questions
What did the European Commission approve for Biocon?
Marketing authorisation for Pebrilzo, Biocon's biosimilar pertuzumab, for HER2-positive breast cancer in the European Union, according to Biocon's 18 November 2026 filing.
What does the EU approval mean for Biocon's business?
It adds a cancer medicine Biocon can sell across the EU, alongside its trastuzumab biosimilar used in the same treatment. Revenue depends on launch timing and pricing, which the filing does not give.
Is Biocon's pertuzumab biosimilar approved in the US?
Yes. Biocon says the EU approval follows a recent US FDA approval for the same biosimilar.
What is the EMA's tailored clinical approach?
It is a newer route in which a biosimilar's approval rests mainly on detailed lab comparisons and pharmacokinetic data, rather than a large efficacy trial in patients. Biocon says its pertuzumab is the first biosimilar approved this way.
This page is educational research based on company filings. It is not a recommendation to buy or sell any security or fund, or personalised investment advice. Investments in securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, enlistment with IAASB and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
